Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
This explains the forecast for the next fiscal year, rather than a revision. In Japan, revenue is expected to decline following the end of sales of Abbott products, while the company will focus on sales of proprietary products, consumables and services. Overseas revenue is expected to increase, including in North America, and the gross profit margin is expected to improve as the product mix changes following the discontinuation of Abbott products. Selling, general and administrative expenses are expected to increase due to higher personnel expenses associated with wage increases and higher depreciation from internal IT investment, while the company will pursue productivity improvements through company-wide earnings reforms.
Early retirement premium payments, etc. ¥2,429 million / Loss on revision of retirement benefit plans ¥850 million / Loss on settlement of asset retirement obligations ¥8 million / Total extraordinary loss ¥3,360 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥232,500 million（-1.1%） |
| Operating profit | Not disclosed → ¥23,500 million（+25.4%） |
| Ordinary income | Not disclosed → ¥23,500 million（+4.2%） |
| Profit attributable to owners of the parent | Not disclosed → ¥15,000 million（+3.4%） |
| Net income per share | Not disclosed → 93.77 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Fiscal Period Covered Fiscal year ending March 2026 / Net Sales ¥235,099 million / Operating profit ¥18,745 million / Ordinary income ¥22,544 million / Profit attributable to owners of the parent ¥14,513 million / Net income per share 89.25 yen and sen |
| Reason for the revision | This explains the forecast for the next fiscal year, rather than a revision. In Japan, revenue is expected to decline following the end of sales of Abbott products, while the company will focus on sales of proprietary products, consumables and services. Overseas revenue is expected to increase, including in North America, and the gross profit margin is expected to improve as the product mix changes following the discontinuation of Abbott products. Selling, general and administrative expenses are expected to increase due to higher personnel expenses associated with wage increases and higher depreciation from internal IT investment, while the company will pursue productivity improvements through company-wide earnings reforms. |
| Details and amount of extraordinary loss | Early retirement premium payments, etc. ¥2,429 million / Loss on revision of retirement benefit plans ¥850 million / Loss on settlement of asset retirement obligations ¥8 million / Total extraordinary loss ¥3,360 million |
| Dividend forecast revision | For the fiscal year ending March 2027, an annual dividend of ¥33 is forecast, comprising an interim dividend of ¥16 and a year-end dividend of ¥17, an increase of ¥1 from the previous fiscal year. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, operating profit declined as domestic revenue fell and selling, general and administrative expenses increased due to measures to address wage increases, research and development investment, and higher depreciation and amortization associated with M&A and capital expenditures. Ordinary profit increased as foreign exchange gains and losses shifted from a loss to a gain. The forecast for the fiscal year ending March 2027 assumes the end of sales of Abbott products, a focus on proprietary products, growth in the North American business and company-wide earnings reforms.